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Abstract
Background: Intravenous thrombolysis (IVT) with alteplase (tissue plasminogen activa-
tor) is the standard pharmacological treatment in acute ischemic stroke (AIS), reducing 
disability in patients.
Aim: To report the results of a thrombolysis protocol taken during 6 years in a regional 
public hospital at Temuco, Chile.
Material and methods: Data from 231 consecutive patients aged 67.1 ± 13.1 years (58.9% 
men) who were treated with IVT, from May 2012 until April 2018, were analyzed.
Results: The median door-to-needle time was 71 min (interquartile range = 53–102). The 
median National Institute of Health Stroke Scale (NIHSS) scores on admission and at 
discharge were 13 and 4 points, respectively. At discharge, 27% of hospitalized patients 
had a favorable outcome, defined as having 0 to 1 points in the modified Rankin scale. 
Symptomatic intracerebral hemorrhage and mortality rates were 5.7 and 13.1%, respec-
tively. The thrombolysis rate rose from 0.7% in 2012 to 5.5% in 2018.
Conclusions: The implementation of 24/7 neurology shifts in the Emergency Department 
allowed us to increase the amount and quality of IVT in our hospital, as measured by the 
rate of thrombolysis and by process indicators such as door-to-needle time.
Keywords: fibrinolytic therapy, stroke, time-to-treatment, thrombolytic therapy, tissue 
plasminogen activator, alteplase
1. Introduction
Stroke is the leading cause of disability and the second cause of death worldwide [1]. 
More than two-thirds of the global burden of stroke occurs in developing countries, where 
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the average age of patients is 15 years younger than in developed countries [2]. In the 
period 2000–2008, the total incidence rates in low- and middle-income countries exceeded 
the level of stroke incidence in high-income countries by 20% for the first time [3]. Stroke 
has become one of the main health problems in many countries of Latin America and the 
Caribbean [4].
In Chile, cerebrovascular diseases (CBVD) are the leading cause of death, with a rate of 
50.6 deaths per 100,000 inhabitants in 2011. In addition, they are the first specific cause of 
disability-adjusted life years (DALY) in older than 74 years and the fifth between 60 and 
74 years [5]. Acute ischemic stroke (AIS) is the most frequent cause of CBVD in Chile and 
represents approximately 65% of all cerebrovascular events [6]. CBVD is the leading cause 
of death in Chile and accounted for 9% of all deaths in 2010 [6]. About 8888 people died in 
Chile in 2010 due to CBVD, and 26,072 were hospitalized with the diagnosis of CBVD in 
Chile in 2009.
The PISCIS population study conducted in Iquique during 2000–2002 gave the following 
information: the total incidence adjusted for age for a first stroke was 140.1 per 100,000 
inhabitants. The incidence rates per 100,000 inhabitants according to the type of stroke 
were: 87.3 for cerebral infarction, 27.6 for intracerebral hemorrhage, and 6.2 for subarach-
noid hemorrhage. About 93% of the new brain strokes occur in people older than 45 years: 
the average age was 66.5 years and 56% of them were men. Mortality at 1 month after a 
first cerebral infarction was 19% and mortality at 6 months was 28%. About 18% of people 
are left with a moderate or severe dependence at 6 months after a cerebral infarction [7]. 
The prevalence of CBVD, according to the National Health Survey (NHS) in 2016–2017 is 
2.6% in the general population, and rises to 8.2% in ≥65 years [8]. A slight increase was 
observed when comparing the prevalence estimated in the 2009–2010 NHS, with 2.2 and 
8.1%, respectively [9].
2. Stroke in the Araucanía region
The incidence rate of CBVD, calculated as a diagnosis of hospital discharge, in the period 
2001–2010, in the Araucanía Sur Health Service, was 961.3 per 100,000 inhabitants/year [10].
According to the data from the 2017 census, the largest number of indigenous people in Chile 
is concentrated in the Araucanía Region. About 34.0% of respondents mentioned belong to 
an indigenous or native people, which is significantly higher than 12.8% at national level 
[11]. Furthermore, according to the 2009–2010 ENS, the Araucanía region has the highest 
prevalence of high systolic blood pressure compared to the other regions. On the other 
hand, the Ninth region (Araucanía), along with the Fifth, Seventh, and Eighth, presents 
double the mortality by stroke compared with the rest of the regions of Chile. Most of the 
increased risk would be given by the prevalence of poverty, diabetes, sedentary lifestyle, 
and overweight [12].
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AIS is the most frequent reason for neurological consultation in the adult emergency service 
(AES) of the Dr. Hernán Henríquez Aravena Hospital (HHHA) in Temuco-Chile, accounting 
for 30.7% of the attentions performed by the neurologist [13]. The HHHA is located in the 
heart of the city of Temuco (310,020 inhabitants), capital of the Ninth region of Araucanía, 
about 670 km south of Santiago de Chile, has 730 beds, and is the only hospital of high com-
plexity of the Araucanía region, and serves a beneficiary population of approximately 800,000 
inhabitants. The HHHA neurology unit does not have its own service and depends on the 
internal medicine service. Our hospital lacks a stroke unit [14].
3. Intravenous thrombolysis in acute ischemic stroke
Intravenous thrombolysis (IVT) with alteplase (tissue plasminogen activator), adminis-
tered up to 4.5 h from the onset of symptoms, is the reference pharmacological treatment 
in AIS, reducing the likelihood of dependence patients [15, 16]. The effectiveness of IVT 
is highly time dependent. Around one in three patients treated with alteplase within 3 h 
of symptom onset, and one in six treated within 4.5 h, achieves significant benefit [17, 18]. 
Since 1996, IVT has been the standard management for acute AIS in developed countries. 
However, IVT has been used in the treatment of AIS on small scale in Latin America and 
the Caribbean but not on a national basis. The time from stroke onset to hospital arrival is 
crucial for thrombolysis to be effective, and studies in Lima-Peru, Montevideo-Uruguay, 
and Joinville-Brazil reported delays in hospital admission. Cost is also an issue, especially 
for public-health systems, which hampers planning of thrombolysis for a subgroup of 
patients with ischemic stroke in Latin America [4]. Although the implementation of IVT 
was rapid in the Chilean private health system [19] since 1997, it was not until 2011 that 
the first experience of an IVT protocol was reported in a public hospital in the country [20]. 
Currently, the rate of thrombolysis in large private clinics in Santiago-Chile is 12%, but in 
public hospitals, it is 6% [5]. This gap seems significant because 80% of the population in 
Chile is served in the public health system.
4. Intravenous thrombolysis in the HHHA
Since May 2012, IVT has been performed in the HHHA, which has face-to-face neurologists 
24/7 in the emergency department since July 2013 [14]. The following is a series of consecu-
tive patients who received IVT, between May 2012 and April 2018. The IVT protocol was 
based on the NINDS (1995) and ECASS III (2008) studies, that is, thrombolysis within 3 h, and 
between 3 and 4.5 h, respectively [15, 16]. In addition, modifications were made considering 
the most recent medical literature [21] and local experience, particularly in relation to age 
(over 80 years) and the relevance of some relative contraindications [22, 23]. Table 1 shows the 
inclusion, exclusion, and precaution criteria of the IVT protocol.
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Inclusion criteria
• Neurological symptoms for a period less than 4.5 h, with defined start time
• Neurological deficit measurable by the NIHSS scalea
• Computed tomography of the brain without signs of intracranial hemorrhage
• Signed informed consent
Exclusion criteria
• Ischemic stroke within the last 3 months
• Traumatic brain injury or central nervous system surgery in the last 3 months
• Acute myocardial infarction within the last 21 days
• Major surgery in the last 14 days or organ biopsy
• History of intracranial hemorrhage
• History of coagulopathy (hemophilia, von Willebrand)
• Gastrointestinal or urinary tract bleeding in the last 21 days
• Use of oral anticoagulants with INRb > 1.7 or new anticoagulants in the last 48 h
• Seizure at the onset of symptoms (except diffusion confirms infarction)
• Noncompressible arterial puncture in the last 7 days
• Lumbar puncture in the last 7 days
• Pregnancy or delivery during the last month
• Known antecedents of neoplasia with risk of bleeding
• Systolic BPc> 185 mmHg and/or diastolic BP > 110 mmHg refractory to intravenous medication
• Evidence of systemic bleeding
• Suspicion of septic embolism or infectious endocarditis
• Rapidly improving symptoms
• NIHSS score < 4
• Glucose concentration < 50 or > 400 mg/dl
• Prolongation of partial-thromboplastin time > 40%
• Platelet count < 100,000/mm3
• Hematocrit < 25%
• Prothrombin time > 15 s
• Hemorrhage or early hemorrhagic transformation
• Extensive constituted infarction
Caution criteria
• Age over 80 years
• Severe neurological deficit (NIHSS score > 22)
• Early signs of extensive infarction (ASPECTSd score < 7)
aNational Institute of Health Stroke scale
bInternational Normalized Ratio
cBlood pressure
dAlberta Stroke Program Early CT Scan score.
Table 1. Criteria for inclusion, exclusion, and precaution for intravenous thrombolysis [14].
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5. Results
In total, 231 patients were treated in the period May 2012–April 2018. The average age of the 
patients was 67.7 years (SD = 12.6), with a median of 69 years and about 56.6% of the patients 
were male (N = 136). The clinical characteristics of the thrombolysed patients are shown in 
Table 2.
Regarding the time parameters, the median of the start-to-door time was 105 min interquartile 
range (IQR): 70.5–156.5. The median door-to-needle time (DNT) was 71 min (IQR: 53–102). 
The median onset-to-needle time was 185 min (IQR: 136–235). The median of the NIHSS 
scale at admission was 13 points (IQR: 8–18). In 79 patients (34.2%), the DNT was ≤60 min. 
Likewise, there was a constant decrease in DNT and a progressive increase in the percentage 
of patients treated in less than 60 min from their admission to emergency (Table 3). In 110 
patients (47.6%), thrombolysis was started within 3 h of evolution of the AIS.
For the first 106 patients treated until April 2016, the clinical classification of the AIS, accord-
ing to the Oxfordshire criteria, was: 44.3% of TACI (total anterior) infarcts stand out, 35.9% of 
PACI (partial anterior) infarcts, 15.1% of POCI (posterior) infarcts, and 4.7% of LACI (lacunar) 
infarcts. The etiologies of the AIS, according to the TOAST classification, are the following: 
23.4% of atherothrombotic cause, 35.9% of cardioembolic cause, 5.7% by arterial dissection, 
5.7% of lacunar infarctions, and 29.3% of indeterminate cause. Regarding the functional result 
of the intervention measured with the modified Rankin Scale (mRS) at discharge (Figure 1), it 
is noteworthy that 27.3% of the patients were discharged without disability (mRS = 0–1). For 
Characteristics Patients
N = 231
Age (average ± SDa) 67.1 ± 13.1
≥ 65 years (%) 143 (61.9%)
Male gender (%) 136 (58.9)
Mapuche ethnicity (%) 20 (8.7)
Discharge mRS 0–1b (%) 42 (26.1%)
Discharge mRS 0–3b (%) 76 (47.2%)
Start-to-door time (median, IQRc) 105 (70.5–156.5)
Door-to-needle time (median, IQRc) 71 (53–102)
Start-to-needle time (median, IQRc) 185 (136–235)
Door-to-needle time ≤ 60 min (%) 79 (34.2)
Start-to-needle time ≤ 180 min (%) 110 (47.6%)
aStandard deviation.
bmodified Rankin Scale.
cInterquartile range.
Table 2. Clinical characteristics of thrombolysed patients.
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this subgroup of patients (N = 106), the median of the NIHSS scale at discharge was 5 points 
(IQR 1–14). The mortality rate was 13.1%. In relation to the causes of death, in seven patients, it 
was due to the AIS. Two cases were due to symptomatic hemorrhagic transformation and four 
patients due to complications not related to the AIS: bronchial cancer, cutaneous focus sepsis, 
pulmonary focus sepsis, and severe pneumonia. In addition, 13 patients with hemorrhagic 
transformation (12.3%) were registered, of whom 6 (5.7%) were symptomatic. Four patients 
Figure 1. Evaluation of disability at discharge in patients with acute ischemic stroke who received intravenous 
thrombolysis [14].
Year N Rate
IVTa
(%)
Median
SDTb
(minutes)
Median
DNTc
(minutes)
Median
SNTd
(minutes)
% DNT ≤ 60 min
2012 5 0.7 24 85 154 0
2013 11 1.2 93 111 200 36.4
2014 24 2 79 97 180.5 8.3
2015 44 3.6 91 71 182.5 43.2
2016 65 5.4 132.5 71.5 207 27.7
2017 58 4.8 104 57 156.5 44.8
2018 24 5.5 153 56 163 41.7
Total 231 3.2 105 71 185 34.2
aIntravenous thrombolysis.
bStart-to-door time.
cDoor-to-needle time.
dStart-to-needle time.
Table 3. Evolution of the thrombolysis rate, time parameters, and percentage of patients who received thrombolysis 
in ≤60 min.
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developed an intrahospital AIS, with a 66-year-old man who suffered cerebral infarction after 
a coronary angiography. On the other hand, IVT plus mechanical thrombectomy was per-
formed in four patients. In this subgroup, a 51-year-old patient died as a result of a malignant 
infarction of the right middle cerebral artery due to an occlusive carotid dissection [14].
In our hospital 1200, AIS is diagnosed per year approximately. Therefore, the rate of throm-
bolysis increased from 0.7% in 2012 to 5.5% in 2018. Table 3 shows the evolution of the num-
ber of patients treated per year, the DNT, and the percentage of subjects treated who were 
thrombolysed within 60 min.
6. Discussion
Intravenous thrombolysis in AIS is feasible to be performed in public hospitals, and particu-
larly in regions of our country. In our series, the median DNT was 71 min. The possible causes 
for the result of this indicator are: emergency service collapsed, delay in prioritization, delay 
in the evaluation by neurologist, delay in the taking of neuroimaging, lack of space in the 
resuscitation box, waiting for the result of exams (INR), etc. In our series, it was not possible to 
assess the disability of the subjects at 3 months. In this sense, early outcome evaluations have 
been used, such as the score on the NIHSS scale on the second and seventh day of evolution of 
the AIS, which have been shown to predict, with adequate accuracy, the functional results at 
3 months [24, 25]. In our study, the median of the NIHSS score at discharge was 4 points, with 
a prethrombolysis score of 13 points (Figure 2). The greater severity of the AIS, compared with 
Figure 2. Evolution of the NIHSS score in 231 patients with acute ischemic stroke treated with intravenous thrombolysis.
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other series, could be explained by the high percentage of TACI infarcts and cardioembolic 
AIS. The 5.7% of symptomatic intracerebral hemorrhages (sICH) observed in our series are 
comparable to that reported in national and foreign studies. For example, a recent meta-analy-
sis of 12 randomized clinical trials of IVT up to 6 h from the onset of symptoms, which included 
7012 patients, reported an ICH rate of 7.7%, with a fatal ICH rate during the first 7 days of 3.6%, 
and a mortality of 8.9% within 7 days, and of 19.1% until the end of the follow-up period [26]. 
When presenting our results, we must emphasize that the HHHA does not have a specific 
infrastructure to attend to neurological patients, that is, a stroke unit. These units have demon-
strated their cost-effectiveness in decreasing mortality and disability due to stroke [27]. In our 
reality, not all thrombolysed patients access the intensive care unit and complete 24–48 h of 
observation in the emergency service, being later hospitalized in the internal medicine service.
The developing world carries the highest burden of stroke mortality and stroke-related dis-
ability. The number of stroke patients receiving alteplase (r-tPA) in the developing world is 
extremely low. Prehospital delay, financial constraints, and lack of infrastructure are main 
barriers of thrombolysis therapy in developing countries [28]. Stroke thrombolysis is cur-
rently used in few developing countries like Brazil, Argentina, Chile, Senegal, Iran, Pakistan, 
China, Thailand, and India. Most of the centers with the infrastructure to deliver thrombolysis 
for stroke are predominantly private sector, and only available in urban areas [29].
The rate of thrombolysis that started with 0.7% for the period May-December 2012 rose to 
5.5% in the period January-April 2016 (Table 3). For this change, we consider that the pres-
ence of the neurologist, since July 2013, in the emergency service in the 24/7 modality has been 
fundamental.
Our thrombolysis rate is comparable with that observed in other Chilean public hospitals, 
but it is very low compared to national private clinics that have reported a rate greater than 
10% [5]. According to our records, 19.1% of patients with AIS consult within 3 h of the start of 
symptoms, with a median of approximately 10 h, until the consultation. We believe that with 
educational campaigns aimed at the community, and the socialization of our IVT protocol to 
the hospitals and health centers of the Araucanía region, we can increase the rate of throm-
bolysis in the medium term. The thrombolysed patients had a shorter duration of hospitaliza-
tion (median of 8 days), considering that the average stay of patients who do not receive IVT 
has been estimated between 14 and 15 days in other public hospitals [30, 31]. Our results, 
which constitute the largest reported series of IVT in AIS, in Chilean public hospitals, fill us 
with satisfaction and optimism. They are also an enormous incentive to continue increasing 
the number of patients treated and continue to improve the quality of care.
7. Future of the acute management of ischemic stroke in the 
Araucanía region
About 80% of the population in Chile is treated in the public health system. On the other hand, 
it is expected that the incidence of stroke will increase significantly in our country due to the 
aging of the population. This is why we see the need to set a reperfusion protocol for acute 
ischemic stroke in the 24/7 modality that includes intravenous thrombolysis and mechanical 
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thrombectomy in selected cases. On the other hand, node hospitals in the region are expected 
to have a scanner in the medium term, which would allow telethrombolysis. We also consider 
the need to have a stroke unit and/or a neurological intermediate unit in our hospital for the 
adequate management of patients with acute stroke. In short, we hope that the HHHA will 
become a comprehensive stroke center.
8. Conclusion
Intravenous thrombolysis in acute ischemic stroke is feasible to be performed in public hos-
pitals, and particularly in regions of our country. The presence of neurologists 24/7 in the 
Emergency Department has allowed us to increase the quantity and quality of IVT in our hos-
pital, measured by thrombolysis rate and by process indicators such as door-to-needle time.
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